Nxstage Medical, Inc. (NXTM) Reports In-Line Q1 EPS; Guides Q2
Tweet
Share
E-mailGet Alerts NXTM Hot Sheet
Price: $30.00 --0%
Financial Fact:
Research and development: 8.28M
Today's EPS Names:
HSAI, SYRS, EGRX, More
Financial Fact:
Research and development: 8.28M
Today's EPS Names:
HSAI, SYRS, EGRX, More
Join SI Premium – FREE
Nxstage Medical, Inc. (NASDAQ: NXTM) reported Q1 EPS of ($0.08), in-line with the analyst estimate of ($0.08). Revenue for the quarter came in at $61.6 million versus the consensus estimate of $61.14 million.
Nxstage Medical, Inc. sees Q2 2013 EPS of $-0.08--0.07, versus the consensus of $-0.07. Nxstage Medical, Inc. sees Q2 2013 revenue of $64.0-65.5 million, versus the consensus of $64.5 million.
For earnings history and earnings-related data on Nxstage Medical, Inc. (NXTM) click here.
Nxstage Medical, Inc. sees Q2 2013 EPS of $-0.08--0.07, versus the consensus of $-0.07. Nxstage Medical, Inc. sees Q2 2013 revenue of $64.0-65.5 million, versus the consensus of $64.5 million.
For earnings history and earnings-related data on Nxstage Medical, Inc. (NXTM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
